Gilead's Acquisition Push Faces Scrutiny Amid Ongoing Diversification Struggles

What happened

Gilead Sciences is doubling down on acquisitions, adding immunology and CAR-T assets to diversify beyond its HIV-dependent revenue stream. However, the DeepValue report reveals that the company's oncology and cell therapy segments are underperforming, with cell therapy revenue guided down ~10% in 2026 due to competitive headwinds. Past diversification efforts have led to recurring IPR&D impairments and Phase 3 setbacks, such as the ASCENT-07 miss for Trodelvy, indicating execution risks in pipeline integration. The new acquisitions come amidst persistent commercialization challenges, including CVS formulary exclusions for Yeztugo, which threaten the $800 million 2026 target for this key growth driver. Thus, while management aims to build a second growth leg, investors should view these moves skeptically until tangible improvements in diversification and payer access materialize.

Implication

The acquisitions highlight management's ongoing diversification efforts but do not mitigate near-term risks, such as cell therapy declines and competitive pressures. Yeztugo's success remains critical and hinges on unresolved payer coverage issues, which acquisitions fail to address directly. Financial flexibility from HIV cash flows enables deal-making, but past impairments suggest caution in expecting rapid returns on investment. Investors should prioritize execution metrics over acquisition announcements, focusing on Yeztugo's quarterly sales and payer access progress. Maintaining a WAIT rating is prudent until mid-2026 data confirms whether diversification efforts yield measurable growth beyond HIV.

Thesis delta

No material shift in the thesis; Gilead remains a HIV cash-flow compounder with Yeztugo as the primary near-term catalyst. Acquisitions reinforce long-term diversification attempts but do not resolve immediate execution risks or cell therapy headwinds. The WAIT stance is unchanged, pending evidence of successful integration and tangible pipeline advancements.